Adovate的动态

Thoughts on this? >> Novartis expands Scemblix label to first-line CML patients >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #biotech #pharmaceutical #pharma #healthcare

Thoughts on this? >> Novartis expands Scemblix label to first-line CML patients >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #pharma #biotech #productmarketing #healthcare

Explore the transformative potential of oligonucleotide therapeutics in addressing unmet medical needs in the pharmaceutical landscape. This insightful article outlines the various types of ONDs, their mechanisms, and the critical role of advanced bioanalytical methods in ensuring their effectiveness and safety. With a focus on the recent surge in regulatory approvals, it underscores the burgeoning role of these targeted therapies in revolutionizing treatment for rare diseases and cancer. #WuXiAppTec https://hubs.li/Q02w2n860

AbbVie’s $8.7 Billion Cerevel Buy Starts to Pay Off with Phase III Parkinson’s Win AbbVie has announced that its investigational Parkinson’s disease drug tavapadon met its primary efficacy endpoint in the Phase III TEMPO-1 trial, showing significant improvements in motor and non-motor symptoms in patients with early-stage disease. Tavapadon was originally developed by Cerevel Therapeutics, which AbbVie acquired for $8.7 billion in December 2023. The companies formally completed the deal last month. AbbVie is also running the TEMPO-4 trial, which will assess the long-term safety and tolerability of tavapadon, and the TEMPO-2 study, which is looking at a flexible-dose regimen of tavapadon monotherapy. Topline data from the latter study are set to come out by the end of 2024. https://lnkd.in/ghki4BsY #aspenalert #biotech #bioprocess

This?week's?Pearce IP?#BioBlast?features the following (and more!):? ? - #ranibizumab: Xbrane Biopharma AB to resubmit BLA for ranibizumab biosimilar following FDA CRL - #pembrolizumab: MSD’s #Keytruda? approved in Canada for new gastric cancer indication - #adalimumab: Alvotech enters further US partnership agreement for adalimumab biosimilar - #infliximab: Celltrion Inc wins Denmark’s national bid for infliximab - #semaglutide: Biocon and Biomm enter agreement to supply generic #Ozempic? in Brazil?? - #ustekinumab: FDA Approves Alvotech & Teva Pharmaceuticals's Selarsdi? - #pembrolizumab: MSD’s #Keytruda? obtains approval for cervical cancer indication in Korea - #tocilizumab: Fresenius Kabi launches biosimilar tocilizumab in the US - #denosumab: Celltrion Inc presents phase 3 results for denosumab biosimilar - #rituximab: Genentech & Dr. Reddy's Laboratories settle US rituximab dispute Read more: https://lnkd.in/g6JrMD3a ? #bioblast?#biosimilars?#boutiquelawfirm?#australia?#patentlaw?#awardwinning?#pearceip #patents #biopharma #lifesciences #femalefounder?

Explore the transformative potential of oligonucleotide therapeutics in addressing unmet medical needs in the pharmaceutical landscape. This insightful article outlines the various types of ONDs, their mechanisms, and the critical role of advanced bioanalytical methods in ensuring their effectiveness and safety. With a focus on the recent surge in regulatory approvals, it underscores the burgeoning role of these targeted therapies in revolutionizing treatment for rare diseases and cancer. #WuXiAppTec https://hubs.li/Q02w2lBk0

Metoprolol-D7 N-Nitroso ? Metoprolol-D7 N-Nitroso is a specialized pharmaceutical product that incorporates deuterium-labeled Metoprolol along with a N-Nitroso moiety. Metoprolol is a beta-blocker primarily used for treating high blood pressure, chest pain (angina), and heart failure. The addition of the N-Nitroso group might suggest potential applications in cancer research or other therapeutic areas where nitroso compounds have shown promise, such as in the modulation of cellular signaling pathways or as potential prodrugs #prasilabspvtltd #prasilabs #MetoprololD7NNitroso

Composition Type would like to congratulate Citius Pharmaceuticals for FDA approval of?LYMPHIR (denileukin diftitox-cxdl) for the treatment of ?Relapsed or Refractory Cutaneous T-Cell Lymphoma! COMPOSITION TYPE We work with all types! ? #pharma #biotech #fdaapproval #citius #lymphoma

Hepatocellular Carcinoma Clinical Trials, Pipeline Insights, Treatment Drugs, and Companies 2024: DelveInsight’s,?“Hepatocellular Carcinoma Pipeline Insight 2024”?report provides comprehensive insights about?90+ companies and 95+ pipeline drugs?in Hepatocellular Carcinoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, … Continue reading → #PharmaceuticalsBiotech